In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05 ...

NASDAQ ROIV opened at $10.66 on Monday. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market capitalization of $7.61 billion, a price-to ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other cash-rich mid cap stocks. Cash flow is the money moving in and out of a business ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...